Publication:
Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region

dc.contributor.buuauthorGöktaş, Olgun
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorErtürk, Erdinç
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentAile Sağlığı Merkezi
dc.contributor.departmentİç Hastalıkları Bölümü
dc.contributor.researcheridAAJ-6536-2021tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.scopusid6603078279tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.date.accessioned2023-08-29T06:17:11Z
dc.date.available2023-08-29T06:17:11Z
dc.date.issued2017-04
dc.description.abstractAim: The aim of the study was to investigate the treatment and monitoring patterns of type 2 diabetes patients in the Bursa region over the last 5 years since the implementation of family practice in Turkey in 2010. Methods: A total of 216 volunteer family doctors working in family health centers took part in this study. The records of 44,819 diabetic patients who visited these doctors between January 1, 2010 and December 31, 2014 were inspected retrospectively. Apart from the identity of the patients, morphometric data, including the type of medication used for diabetes and the HbA1C, serum creatinine and LDL cholesterol values, were recorded. Results: A total of 38.9% (17,416 patients) of the patients in the study were male and 61.1% (27,403 patients) were female. The average age was 59.7 years with a range of 13.2 years. Although the patients' average body mass index (BMI) did not change over the 5 years monitoring, average blood pressure (BP), and serum creatinine and LDL cholesterol levels decreased significantly. The hemoglobin A1c levels were significantly lower after 2010 compared to the 2010 data. Upon examining the medication prescribed for the patients, we determined that the use of metformin and insulin increased, whereas the prescription of thiazolidinedione (glitazone) decreased. There was a significant increase in the amount of patient data recorded over the last 5 years. Conclusions: Despite the increased level of data entry in these patients with type 2 diabetes, the surveillance of diabetes parameters according to treatment guidelines remains suboptimal. There continues to be a need to engage family practitioners on ongoing education and practice enhancement programs.en_US
dc.identifier.citationGöktaş, O. vd. (2017). ''Changes in the management of type 2 diabetic patients in family medicine practices in the Bursa region''. Primary Care Diabetes, 11(2), 178-183.en_US
dc.identifier.endpage183tr_TR
dc.identifier.issn1751-9918
dc.identifier.issn1878-0210
dc.identifier.issue2tr_TR
dc.identifier.pubmed27852516tr_TR
dc.identifier.scopus2-s2.0-85008174113tr_TR
dc.identifier.startpage178tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.pcd.2016.10.004
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1751991816301073
dc.identifier.urihttp://hdl.handle.net/11452/33658
dc.identifier.volume11tr_TR
dc.identifier.wos000396955300011
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.journalPrimary Care Diabetesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocrinology & metabolismen_US
dc.subjectGeneral & internal medicineen_US
dc.subjectDiabetes mellitusen_US
dc.subjectFamily medicineen_US
dc.subjectMonitoring of diabetesen_US
dc.subjectTreatment of diabetesen_US
dc.subjectBursa-Turkeyen_US
dc.subjectEuropean associationen_US
dc.subjectPrescribing trendsen_US
dc.subjectHyperglycemiaen_US
dc.subjectStatementen_US
dc.subjectCareen_US
dc.subject.emtreeAcarboseen_US
dc.subject.emtreeAntidiabetic agenten_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeDipeptidyl peptidase IV inhibitoren_US
dc.subject.emtreeGlitazone derivativeen_US
dc.subject.emtreeGlucoseen_US
dc.subject.emtreeHemoglobin A1cen_US
dc.subject.emtreeInsulinen_US
dc.subject.emtreeLow density lipoprotein cholesterolen_US
dc.subject.emtreeMeglitinideen_US
dc.subject.emtreeMetforminen_US
dc.subject.emtreeSulfonylurea derivativeen_US
dc.subject.emtreeAntidiabetic agenten_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeHemoglobin A1c proteinen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood pressure monitoringen_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeCholesterol blood levelen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeDrug useen_US
dc.subject.emtreeFamily medicineen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGeneral practiceen_US
dc.subject.emtreeGeneral practitioneren_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeHemoglobin blood levelen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInsulin treatmenten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMedical record reviewen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMorphometryen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePatient monitoringen_US
dc.subject.emtreePrescriptionen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeClinical practiceen_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeGeneral practiceen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeHealth care disparityen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePractice guidelineen_US
dc.subject.emtreeProtocol complianceen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeTime factoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTrendsen_US
dc.subject.meshAgeden_US
dc.subject.meshBiomarkersen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshFamily practiceen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycated hemoglobin Aen_US
dc.subject.meshGuideline adherenceen_US
dc.subject.meshHealthcare disparitiesen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPhysicians, familyen_US
dc.subject.meshPractice guidelines as topicen_US
dc.subject.meshPractice patterns, physiciansen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusAntidiabetic Agent; Biguanide Derivative; Hypoglycemic Agentsen_US
dc.subject.wosEndocrinology & metabolismen_US
dc.subject.wosPrimary health careen_US
dc.titleChanges in the management of type 2 diabetic patients in family medicine practices in the Bursa regionen_US
dc.typeArticle
dc.wos.quartileQ4 (Endocrinology & metabolism)en_US
dc.wos.quartileQ3 (Primary health care)en_US
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Aile Sağlığı Merkezi/Aile Hekimliği Ana Bilim Dalıtr_TR
local.contributor.departmentTıp Fakültesi/Endokrinoloji ve Metabolizma Ana Bilim Dalı/İç Hastalıkları Bölümütr_TR

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: